Using Platelet-Rich Plasma to treat Peyronie's Disease
Treatment of Peyronie's Disease with Platelet-Rich Plasma: a Pilot Study
NA · Herlev Hospital · NCT06789510
This study is testing whether injections of Platelet-Rich Plasma can help men with Peyronie's disease during its early stage to see if it could be a good treatment option.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Herlev Hospital (other) |
| Locations | 1 site (Herlev) |
| Trial ID | NCT06789510 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to optimize a future randomized, double-blind, placebo-controlled clinical trial that will evaluate the effects of Platelet-Rich Plasma (PRP) injections in men suffering from Peyronie's disease during its fibrotic phase. Participants will undergo a baseline assessment and then receive a series of PRP and saline injections over six weeks in a randomized order. The study will also identify potential challenges in executing the clinical trial, particularly in PRP preparation and maintaining the blinding process. Follow-up assessments will occur three months after the final injection to evaluate the treatment's effects.
Who should consider this trial
Good fit: Ideal candidates are men aged 18 and older with a diagnosis of Peyronie's disease in the fibrotic phase and a penile curvature of 30-95 degrees.
Not a fit: Patients with erectile dysfunction unresponsive to PDE5 inhibitors, severe penile malformations, or a history of priapism or penile fracture may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for men suffering from Peyronie's disease.
How similar studies have performed: While the use of PRP in treating Peyronie's disease is a relatively novel approach, similar studies in other conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Be able to provide written informed consent * Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase). * Penile curvature of 30-95 degrees Exclusion Criteria: * Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors * Hourglass malformation * Severely calcified plaques where injection is considered unfeasible * History of priapism. * History of penile fracture. * Previous treatment for PD with injections and/or surgery.
Where this trial is running
Herlev
- Herlev and Gentofte University Hospital — Herlev, Denmark (RECRUITING)
Study contacts
- Study coordinator: Mikael Heering, MD
- Email: mikael.heering@regionh.dk
- Phone: +4538688964
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Peyronies Disease, PRP, Platelet-Rich Plasma